Fluoxetine
- Generic Name
- Fluoxetine
- Brand Names
- Prozac, Sarafem, Symbyax
- Drug Type
- Small Molecule
- Chemical Formula
- C17H18F3NO
- CAS Number
- 54910-89-3
- Unique Ingredient Identifier
- 01K63SUP8D
- Background
Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies.
- Indication
Fluoxetine is indicated for both acute and maintenance treatment of major depressive disorder, obsessive compulsive disorder, and bulimia nervosa; however, it is only indicated for acute treatment of panic disorder independent of whether agoraphobia is present. Fluoxetine may also be used in combination with olanzapine to treat depression related to Bipolar ...
- Associated Conditions
- Alcohol Dependency, Anorexia Nervosa (AN), Bulimia Nervosa, Cataplexy, Depression, Major Depressive Disorder (MDD), Major depressive disorder, recurrent episode, Myoclonus, Obesity, Obsessive Compulsive Disorder (OCD), Panic Disorder With Agoraphobia, Panic disorder without agoraphobia, Premature Ejaculation, Premenstrual Dysphoric Disorder (PMDD)
- Associated Therapies
- Maintenance therapy
Poststroke Depression in Hemorrhagic Stroke
- First Posted Date
- 2019-02-01
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 224
- Registration Number
- NCT03826875
- Locations
- 🇺🇸
Harborview Medical Center, Seattle, Washington, United States
Vortioxetine in the Elderly vs. Selective Serotonin Reuptake Inhibitors (SSRIs): a Pragmatic Assessment
- Conditions
- Interventions
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2023-05-19
- Target Recruit Count
- 362
- Registration Number
- NCT03779789
- Locations
- 🇮🇹
Azienda Ospedaliera Universitaria Mater Domini, Università Magna Grecia, Catanzaro, Italy
🇮🇹Sapienza Università di Roma, Dipartimento di Neurologia e Psichiatria, Roma, Italy
🇮🇹Azienda Ospedaliera Universitaria Verona, Verona, Italy
Fluoxetine in Pulmonary Arterial Hypertension (PAH) Trial
- First Posted Date
- 2018-08-20
- Last Posted Date
- 2020-06-26
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 8
- Registration Number
- NCT03638908
- Locations
- 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
Efficacy, Safety, and Tolerability of Levomilnacipran ER in Pediatric Patients (7-17 Years) With Major Depressive Disorder
- Conditions
- Interventions
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2022-03-25
- Lead Sponsor
- Allergan
- Target Recruit Count
- 501
- Registration Number
- NCT03569475
- Locations
- 🇺🇸
Manhattan Behavioral Medicine, PLLC, New York, New York, United States
🇺🇸AMR Conventions Limited, Naperville, Illinois, United States
🇺🇸AMR-Baber Research, Inc., Naperville, Illinois, United States
Bariatric Surgery and Pharmacokinetics of Fluoxetine
- Conditions
- First Posted Date
- 2018-03-26
- Last Posted Date
- 2023-04-13
- Lead Sponsor
- Norwegian University of Science and Technology
- Target Recruit Count
- 12
- Registration Number
- NCT03476525
- Locations
- 🇳🇴
St. Olavs University Hospital, Trondheim, Norway
SMART-DAPPER: Leveraging the Depression And Primary-care Partnership for Effectiveness-implementation Research Project
- Conditions
- Interventions
- First Posted Date
- 2018-03-15
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 2162
- Registration Number
- NCT03466346
- Locations
- 🇰🇪
Kisumu County Hospital, Kisumu, Kenya
🇰🇪Lumumba Health Center, Kisumu, Kenya
🇰🇪Jaramogi Oginga Odinga Teaching and Referral Hospital (JOOTRH), Kisumu, Kenya
OxSYPan: Oxford Study With Young People on Antidepressants
- First Posted Date
- 2018-02-19
- Last Posted Date
- 2018-02-20
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 32
- Registration Number
- NCT03436173
Identifying and Treating Depression in Hemodialysis Patients
- First Posted Date
- 2018-01-05
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- MetroHealth Medical Center
- Target Recruit Count
- 16
- Registration Number
- NCT03390933
- Locations
- 🇺🇸
MetroHealth Medical Center, Cleveland, Ohio, United States
The Effects of Fluoxetine And/or DHEA
- Conditions
- Interventions
- First Posted Date
- 2017-07-25
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 60
- Registration Number
- NCT03228732
- Locations
- 🇺🇸
University of Maryland, Baltimore, Maryland, United States
Multi-Dimensional Diagnosis,Individualized Therapy,and Management Technique for Major Depressive Disorder:Based on Clinical and Pathological Characteristics
- Conditions
- Interventions
- Combination Product: fluoxetine + cognitive-behavioral treatment（CBT）Drug: fluoxetine + AmfebutamoneCombination Product: physical treatment+fluoxetine+amfebutamoneCombination Product: Cognitive behavior treatment +fluvoxamineDrug: Lithium+fluvoxamineCombination Product: fluvoxamine + lithium + physical therapyDrug: Mirtazapine/SNRIsCombination Product: mirtazapine+ Cognitive behavior treatmentDrug: mirtazapine + SNRIsCombination Product: mirtazapine + SNRIs + physical therapyOther: TAU(treat as usual)Drug: FluoxetineDrug: Fluvoxamine
- First Posted Date
- 2017-07-17
- Last Posted Date
- 2017-10-10
- Lead Sponsor
- Shanghai Mental Health Center
- Target Recruit Count
- 800
- Registration Number
- NCT03219008
- Locations
- 🇨🇳
ShanghaiMHC, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.